Clive Page
- Long-acting bronchodilators in COPD: where are we now and where are we going?By Mario Cazzola and Clive PageMario Cazzola1Unit of Respiratory Clinical Pharmacology, Dept of System Medicine, University of Rome Tor Vergata, Rome, ItalyClive Page2Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK
- The effect of M. tuberculosis chaperonin 60.1 on leukocyte migrationBy Yanira Riffo-Vasquez, Anthony Coates, Clive Page and Domenico SpinaYanira Riffo-Vasquez1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomAnthony Coates2Helperby Therapeuthics Limited, Helperby Therapeuthics Limited, London, United KingdomClive Page1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomDomenico Spina1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United Kingdom
- Late-breaking abstract: Further studies on the mechanism of action of doxofyllineBy Thierry Jolas, Clive Page and Luigi AllegraThierry Jolas1Scientific Director, CEREP, Celle l'Evescault, FranceClive Page2Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, United KingdomLuigi Allegra3Pneumology, IRCCS Policlinical Hospital, Milan, Italy
- Late-breaking abstract: Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthmaBy Christopher Hewson, Sheena Patel, Luigino Calzetta, Hinnah Campwala, Suzanne Havard, Emma Luscombe, Philip Clarke, Peter Peachell, Maria Matera, Mario Cazzola, Clive Page, William Abraham, Cara Williams, James Clark, Nicholas Clarke and Michael YeadonChristopher Hewson1Allergy & Respiratory Research Unit, Pfizer, Sandwich, Kent, United KingdomSheena Patel1Allergy & Respiratory Research Unit, Pfizer, Sandwich, Kent, United KingdomLuigino Calzetta2Unit of Respiratory Clinical Pharmacology, Dept. Internal Medicine, University of Rome “Tor Vergata”, Rome, ItalyHinnah Campwala1Allergy & Respiratory Research Unit, Pfizer, Sandwich, Kent, United KingdomSuzanne Havard3Academic Unit of Respiratory Medicine, University of Sheffield, Sheffield, S Yorks, United KingdomEmma Luscombe1Allergy & Respiratory Research Unit, Pfizer, Sandwich, Kent, United KingdomPhilip Clarke1Allergy & Respiratory Research Unit, Pfizer, Sandwich, Kent, United KingdomPeter Peachell3Academic Unit of Respiratory Medicine, University of Sheffield, Sheffield, S Yorks, United KingdomMaria Matera4Unit of Pharmacology, Dept. Experimental Medicine, Second University of Naples, Naples, ItalyMario Cazzola2Unit of Respiratory Clinical Pharmacology, Dept. Internal Medicine, University of Rome “Tor Vergata”, Rome, ItalyClive Page5Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomWilliam Abraham6Dept. Research, Mount Sinai Medical Center, Miami Beach, FL, United StatesCara Williams7Inflammation & Immunity Research Unit, Pfizer, Cambridge, MA, United StatesJames Clark7Inflammation & Immunity Research Unit, Pfizer, Cambridge, MA, United StatesNicholas Clarke1Allergy & Respiratory Research Unit, Pfizer, Sandwich, Kent, United KingdomMichael Yeadon1Allergy & Respiratory Research Unit, Pfizer, Sandwich, Kent, United Kingdom
- MKK3 is expressed in cells from patients with allergic asthmaBy Tatjana Holand, Yanira Riffo-Vasquez, Domenico Spina, Brian O'Connor, Francis Woisin, Mike Barber, Kevin Bacon, Christian Rohlff and Clive PageTatjana Holand1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomYanira Riffo-Vasquez1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomDomenico Spina1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomBrian O'Connor1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomFrancis Woisin1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomMike Barber2Cardiovascular Research Division, King's College London, London, United KingdomKevin BaconChristian RohlffClive Page1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United Kingdom
- Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary diseaseBy Clive Page and Mario CazzolaClive Page1Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UKMario Cazzola2Unit of Respiratory Clinical Pharmacology, Dept of System Medicine, University of Rome “Tor Vergata”, Rome, Italy
- Anti-inflammatory activity of doxofylline and theophylline in LPS-induced lung inflammationBy Yanira Riffo-Vasquez and Clive PageYanira Riffo-Vasquez1Sackler Institute of Pulmonary Pharmacology, King's College London, United KingdomClive Page1Sackler Institute of Pulmonary Pharmacology, King's College London, United Kingdom
- The effect of N acetyl-de-O-sulphated heparin on leukocyte diapedesis in vivoBy Yanira Riffo-Vasquez, Alysha Somani and Clive PageYanira Riffo-Vasquez1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomAlysha Somani1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomClive Page1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United Kingdom
- Effect of doxofylline on LPS-induced leukocyte migration to the lungBy Yanira Vasquez, Francis Man and Clive PageYanira Vasquez1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomFrancis Man1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomClive Page1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United Kingdom
- Validation of a hypertussive model of cough in the rabbitBy Emlyn Clay, Domenico Spina and Clive PageEmlyn Clay1Institute of Pharmacological Sciences, King's College London, London, United KingdomDomenico Spina1Institute of Pharmacological Sciences, King's College London, London, United KingdomClive Page1Institute of Pharmacological Sciences, King's College London, London, United Kingdom
- Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary diseaseBy Clive Page and Mario CazzolaArticle | Published in 2014 in European Respiratory JournalClive Page1Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UKMario Cazzola2Unit of Respiratory Clinical Pharmacology, Dept of System Medicine, University of Rome “Tor Vergata”, Rome, Italy
- Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lungBy Yanira Vasquez and Clive PageYanira Vasquez1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomClive Page1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United Kingdom
- A molecule derived from mycobacterium tuberculosis Cpn60.1 (compound Y) inhibits lung inflammation induced by LPS in miceBy Yanira Vasquez, Andrew Lightfoot and Clive PageYanira Vasquez1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomAndrew Lightfoot2Peptinnovate Ltd., Peptinnovate Ltd., London, United KingdomClive Page1Sackler Institute of Pulmonary Pharmacology, King's College London, London, United Kingdom
- Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchiBy Luigino Calzetta, Mario Cazzola, Clive Page, Paola Rogliani, Francesco Facciolo and Maria Gabriella MateraLuigino Calzetta1Department of Respiratory Rehabilitation, San Raffaele Pisana Hospital, IRCCS, Rome, ItalyMario Cazzola2Department of System Medicine, University of Rome ‘Tor Vergata’, Rome, ItalyClive Page3Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United KingdomPaola Rogliani2Department of System Medicine, University of Rome ‘Tor Vergata’, Rome, ItalyFrancesco Facciolo4Thoracic Surgery, Regina Elena National Cancer Institute, Rome, ItalyMaria Gabriella Matera5Department of Experimental Medicine, Second University of Naples, Naples, Italy
- Interaction between RPL554 and glycopyrronium bromide in small human airwaysBy Luigino Calzetta, Mario Cazzola, Clive Page, Paola Rogliani, Francesco Facciolo and Maria Gabriella MateraLuigino Calzetta1Department of Respiratory Rehabilitation, San Raffaele Pisana Hospital, IRCCS, Rome, ItalyMario Cazzola2Department of System Medicine, University of Rome ‘Tor Vergata’, Rome, ItalyClive Page3Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, United KingdomPaola Rogliani2Department of System Medicine, University of Rome ‘Tor Vergata’, Rome, ItalyFrancesco Facciolo4Thoracic Surgery, Regina Elena National Cancer Institute, Rome, ItalyMaria Gabriella Matera5Department of Experimental Medicine, Second University of Naples, Naples, Italy
- Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysisBy Mario Cazzola, Luigino Calzetta, Clive Page, Josè Jardim, Alexander G. Chuchalin, Paola Rogliani and Maria Gabriella MateraMario Cazzola1Dept of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyLuigino Calzetta1Dept of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyClive Page2Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UKJosè Jardim3Respiratory Diseases, Escola Paulista de Medicina of Federal University of Sao Paulo, Sao Paulo, BrazilAlexander G. Chuchalin4Institute of Pulmonology, Federal Medical and Biological Agency, Moscow, RussiaPaola Rogliani1Dept of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyMaria Gabriella Matera5Dept of Experimental Medicine, Second University of Naples, Naples, Italy
- The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated tracheaBy Radhakrishnan Venkatasamy, Clive Page and Domenico SpinaRadhakrishnan VenkatasamySackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomClive PageSackler Institute of Pulmonary Pharmacology, King's College London, London, United KingdomDomenico SpinaSackler Institute of Pulmonary Pharmacology, King's College London, London, United Kingdom
- Cardiovascular Complications of Respiratory Disorders
Edited by Miguel Ángel Martínez-García, Jean-Louis Pépin and Mario CazzolaBook | Published in 2020DOI: 10.1183/2312508X.erm8820ISBN (electronic): 978-1-84984-119-1Miguel Ángel Martínez-GarcíaJean-Louis Pépin
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
